Mechanism of Action for BELVIQ® and BELVIQ XR®



  • BELVIQ and BELVIQ XR are not stimulants or narcotics.2,4 They are federally controlled substances (CIV) because they may be abused or lead to dependence
  • BELVIQ and BELVIQ XR are the only selective 5-HT2C receptor agonists for chronic weight management1,4
  • At the recommended daily dose, BELVIQ and BELVIQ XR selectively interact with 5-HT2C receptors as compared with 5-HT2A and 5-HT2B receptors1
  1. BELVIQ®/BELVIQ XR® [package insert]. Woodcliff Lake, NJ: Eisai Inc; 2016.
  2. Data on file. Woodcliff Lake, NJ: Eisai Inc; 2009.
  3. NA
  4. Thomsen WJ, Grottick AJ, Menzaghi F, et al. Lorcaserin, a novel selective human 5-hydroxytryptamine 2C agonist: in vitro and in vivo pharmacological characterization. J Pharmacol Exp Ther. 2008;325(2):577-587.
  5. Pithadia AB, Jain SM. 5-Hydroxytryptamine receptor subtypes and their modulators with therapeutic potentials. J Clin Med Res. 2009;1(2):72-80.
  6. Hoyer D, Clarke DE, Fozard JR, et al. VII. International Union of pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev.1994;46(2):157-203.
  7. Nichols CD. Serotonin 5-HT2A receptor function as a contributing factor to both neuropsychiatric and cardiovascular diseases. Cardiovasc Psychiatry Neurol. Volume 2009;2009:475108. doi:10.1155/2009/4751088.
  8. Rothman RB, Baumann MH, Savage JE, et al. Evidence for possible involvement of 5-HT2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation. 2000;102:2836-2841.

View Clinical Video Presentation

View Clinical Video Presentation

video overlay image